Remdesivir output up, but supply bottlenecks remain × The production of most sought after anti-viral drug, Remdesivir, has increased significantly but its availability continues to be a challenge in some States and private hospitals. The production capacity of the remdesivir injection by seven domestic manufacturers has increased from 38 lakh vials per month to nearly 119 lakh vials, the Ministry of Chemicals and Fertilisers said on Monday. Developed by US-based Gilead Sciences Inc, Remdesivir is being used to treat Covid-19 patients with oxygen saturation below 95 per cent and those with moderate to severe symptoms. Hyderabad-based Hetero Drugs is a major manufacturer of Remdisivir followed by Cipla, Zydus Cadila, Mylan Labs, Dr Reddy’s Labs, Syngene and Jubilant Ingrevia.